Otsuka, Bristol-Myers Squibb Withdraw Abilify Extension Application In Europe
This article was originally published in PharmAsia News
Executive Summary
Japan's fifth-largest drug maker Otsuka Pharmaceutical withdrew its application in Europe for the additional indication of major depressive episodes for its best-selling atypical antipsychotic Abilify (aripiprazole), the European Medicines Agency announced Nov. 19
You may also be interested in...
BMS' Abilify Gains Third Pediatric Indication: Autism-Related Irritability
New claim puts the atypical antipsychotic on par with J&J's Risperdal.
BMS & Otsuka Expand Their Abilify Deal, Enter into New Oncology Co-Promotion
Bristol-Myers Squibb and Japanese partner Otsuka Pharmaceuticals have entered into a two-part deal that extends their 10-year-old collaboration to sell the blockbuster psychiatric drug Abilify (aripiprazole) in the U.S. and also gives Otsuka a presence in oncology in the U.S., Europe and Japan
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).